EGFR Inhibitor 2 is a potent, selective small molecule inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase, commonly used as a research reagent in oncology and cell biology studies. It binds to the ATP-binding site of EGFR, blocking its phosphorylation and downstream signaling pathways such as PI3K/AKT and MAPK, which are critical for cell proliferation and survival. This compound is particularly valuable in investigating EGFR-driven cancers, including non-small cell lung cancer (NSCLC) with EGFR mutations (e.g., exon 19 deletions or L858R). It is employed in cell-based assays, kinase activity screens, and preclinical models to evaluate targeted therapy mechanisms, drug resistance, and combination effects with other inhibitors. With high purity (typically ≥98%), it serves as a tool for probing EGFR signaling in personalized medicine research and drug discovery.